Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer

Matteo Puntoni, Marilena Petrera, Sara Campora, Elsa Garrone, Carlotta Defferrari, Rosalba Maria Concetta Torrisi, Harriet Ann Johansson, Silvia Bruno, Antonio Curotto, Andrea DeCensi

Research output: Contribution to journalArticle

Abstract

Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993-1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P ≥ 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P =0.02), CS (P =0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (≥350 pg/mL) had a significantly shorter OS (P =0.01), CS (P = 0.02), and BCS (P= 0.008). The trend across quintiles of VEGF was significant for BCS (P =0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR =2.7; 95% CI, 1.1-6.5), CS (HR = 3.3; 95% CI, 1.1-9.4) and BCS (HR =8.9; 95% CI,1.3-61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437-44.

Original languageEnglish
Pages (from-to)437-444
Number of pages8
JournalCancer Prevention Research
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Fenretinide
Urinary Bladder Neoplasms
Vascular Endothelial Growth Factor A
Survival
Neoplasms
Retinoids
Aneuploidy
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer. / Puntoni, Matteo; Petrera, Marilena; Campora, Sara; Garrone, Elsa; Defferrari, Carlotta; Torrisi, Rosalba Maria Concetta; Johansson, Harriet Ann; Bruno, Silvia; Curotto, Antonio; DeCensi, Andrea.

In: Cancer Prevention Research, Vol. 9, No. 6, 01.06.2016, p. 437-444.

Research output: Contribution to journalArticle

Puntoni, Matteo ; Petrera, Marilena ; Campora, Sara ; Garrone, Elsa ; Defferrari, Carlotta ; Torrisi, Rosalba Maria Concetta ; Johansson, Harriet Ann ; Bruno, Silvia ; Curotto, Antonio ; DeCensi, Andrea. / Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 6. pp. 437-444.
@article{c53f3366ad5e42ac807d06560ebe612b,
title = "Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer",
abstract = "Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993-1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P ≥ 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P =0.02), CS (P =0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (≥350 pg/mL) had a significantly shorter OS (P =0.01), CS (P = 0.02), and BCS (P= 0.008). The trend across quintiles of VEGF was significant for BCS (P =0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR =2.7; 95{\%} CI, 1.1-6.5), CS (HR = 3.3; 95{\%} CI, 1.1-9.4) and BCS (HR =8.9; 95{\%} CI,1.3-61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437-44.",
author = "Matteo Puntoni and Marilena Petrera and Sara Campora and Elsa Garrone and Carlotta Defferrari and Torrisi, {Rosalba Maria Concetta} and Johansson, {Harriet Ann} and Silvia Bruno and Antonio Curotto and Andrea DeCensi",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0345",
language = "English",
volume = "9",
pages = "437--444",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Prognostic significance of VEGF after twenty-year follow-up in a randomized trial of fenretinide in non-muscle-invasive bladder cancer

AU - Puntoni, Matteo

AU - Petrera, Marilena

AU - Campora, Sara

AU - Garrone, Elsa

AU - Defferrari, Carlotta

AU - Torrisi, Rosalba Maria Concetta

AU - Johansson, Harriet Ann

AU - Bruno, Silvia

AU - Curotto, Antonio

AU - DeCensi, Andrea

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993-1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P ≥ 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P =0.02), CS (P =0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (≥350 pg/mL) had a significantly shorter OS (P =0.01), CS (P = 0.02), and BCS (P= 0.008). The trend across quintiles of VEGF was significant for BCS (P =0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR =2.7; 95% CI, 1.1-6.5), CS (HR = 3.3; 95% CI, 1.1-9.4) and BCS (HR =8.9; 95% CI,1.3-61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437-44.

AB - Non-muscle-invasive bladder cancer (NMIBC) may progress to muscle-invasive disease, but no effective preventive treatments are available. In addition, no reliable prognostic biomarkers have been identified. We assessed the long-term effect of the oral retinoid fenretinide and the prognostic value of circulating VEGF levels. We updated through the Tumor Registry the vital status of 99 patients with resected Ta/T1 bladder tumors who were recruited in a randomized trial of 2 years of fenretinide or no treatment in 1993-1994. Serum VEGF levels measured at baseline and 12 months were available in a subgroup of 62 patients. After a median of 20.5 years, 54 subjects died, 35 of any cancer and 14 of bladder cancer. Neither overall survival (OS), nor cancer survival (CS) or bladder cancer survival (BCS) was affected by fenretinide (log-rank P ≥ 0.2). DNA aneuploidy in bladder washing was associated with shorter OS (P =0.02), CS (P =0.05), and BCS (P = 0.09). Subjects with baseline VEGF levels in the top quintile (≥350 pg/mL) had a significantly shorter OS (P =0.01), CS (P = 0.02), and BCS (P= 0.008). The trend across quintiles of VEGF was significant for BCS (P =0.007). Multivariate analyses showed that, in addition to smoking status, VEGF level in the top quintile was an independent prognostic factor for OS (HR =2.7; 95% CI, 1.1-6.5), CS (HR = 3.3; 95% CI, 1.1-9.4) and BCS (HR =8.9; 95% CI,1.3-61). Fenretinide did not affect the long-term outcome of patients with NMIBC. High serum VEGF level was a significant predictor of overall and cancer death and may help to identify high-risk subjects who may benefit from a preventive therapy. Cancer Prev Res; 9(6); 437-44.

UR - http://www.scopus.com/inward/record.url?scp=84973120850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973120850&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0345

DO - 10.1158/1940-6207.CAPR-15-0345

M3 - Article

VL - 9

SP - 437

EP - 444

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 6

ER -